We wish you all a very Happy Holiday season and look forward to a tremendous 2023!

Dear all,

We are approaching the holiday season and the closing of one year and opening of another. At CLS we can look back on an exciting year where we have made significant progress towards our vision that laser ablation will be introduced as standard treatment in focal therapy and as an alternative to traditional surgery and, in the longer term, as a complementary systemic treatment of metastasized cancer.

An important milestone for CLS was the launch of our new generation of TRANBERG® products for minimally invasive laser ablation treatment of localized prostate cancer in our markets for urology in Europe and the US. As part of this launch, we introduced our TRANBERG® systems to urologists and oncologists at several regional and international medical conferences during the year. We have also collected further supporting clinical evidence linked to the use of our products in the field of urology.

Another highlight for CLS was the US FDA 510(k) clearance that we obtained for the use of our system in neurosurgery. This great achievement, combined with our first major order, marked the start of the commercial collaboration with our global distributor ClearPoint Neuro, Inc. Our system is also being evaluated in a clinical study performed at Skåne University Hospital in Lund, Sweden. The first patient with recurrent malignant brain cancer, glioblastoma, was treated at the end of the year. This was the first time in Sweden that treatment was performed inside the MRI suite without the patient having to be transported from surgery first.

It goes without saying that all achievements of the past year are thanks to our great team at CLS. In order for us to continue establishing and commercializing our product portfolio in the markets where we are active, we have also grown the team during the year to cater for that expansion.

We look forward to an exciting 2023 in which we hope our treatments will benefit even more patients suffering from severe diseases.

Merry Christmas and a Happy New Year!

Dan J. Mogren

CEO, Clinical Laserthermia Systems AB

Further details from 2022 are provided here.

Welcome to Clinical Laserthermia Systems.

Please note that all our products and indications are not yet approved in all markets. Don’t hesitate to contact us for up-to-date market approvals in your area!

Please choose your country or region